Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1990 Jan;79(1):109–114. doi: 10.1111/j.1365-2249.1990.tb05136.x

Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal.

J Woo 1, C S Ross 1, J I Milton 1, A W Thomson 1
PMCID: PMC1534720  PMID: 1689226

Abstract

Rats were immunized systemically with sheep red blood cells (SRBC) and given either FK-506 (1 mg/kg) or drug vehicle by i.m. injection for 7 days. In animals receiving FK-506, there was suppression (87%) of the splenic plaque-forming cell response on day 4 and marked reductions in the serum antibody titre throughout the 3-week period following immunization. Sequential flow cytometric analyses of blood lymphocytes revealed statistically significant attenuation, by FK-506, of the increase in relative numbers of OX-12+ (B) cells between days 4 and 7. Following drug withdrawal, OX-12 values remained elevated, whereas in control animals a decline was observed. These changes were reflected in concomitant increases in the relative numbers of OX-19+ (CD3+), W3/25+ (CD4+) and OX-8+ (CD8+) T cells; however, due to an overall reduction in lymphocytes by day 7, absolute values were not significantly affected compared with controls. The pattern of changes in OX-6+ (MHC class II+) cells in blood was similar to that observed for B cells. FK-506 also suppressed increases in the small proportion of blood-borne OX-40+ (activated CD4+) cells and OX-39+ (interleukin-2 receptor+) cells in the 7 day period following immunization; thereafter values for activation marker expression between treatment and control groups were similar. In the spleen, there were fewer significant differences between FK-506 and control groups in the incidences of cells expressing the above markers. OX-8+ cells, however, were significantly higher in drug-treated animals on day 7, and there were also reductions in the small proportions of OX-39+ and OX-40+ cells when compared with controls. In the thymus, reversible medullary atrophy induced by FK-506 was accompanied on day 7 by increases in the incidence of CD4+ and CD8+ cells and by a concomitant reduction in OX-44+ mature, medullary thymocytes. Two weeks after drug withdrawal, the phenotypic marker expression profile had been restored to normal in blood, spleen and thymus. These data provide new information on the apparent capacity of FK-506 to interfere with T cell maturation and its influence on lymphocyte activation in vivo.

Full text

PDF
109

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beschorner W. E., Namnoum J. D., Hess A. D., Shinn C. A., Santos G. W. Cyclosporin A and the thymus. Immunopathology. Am J Pathol. 1987 Mar;126(3):487–496. [PMC free article] [PubMed] [Google Scholar]
  2. Collier D. S., Thiru S., Calne R. Kidney transplantation in the dog receiving FK-506. Transplant Proc. 1987 Oct;19(5 Suppl 6):62–62. [PubMed] [Google Scholar]
  3. Cunningham A. J., Szenberg A. Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology. 1968 Apr;14(4):599–600. [PMC free article] [PubMed] [Google Scholar]
  4. Harel-Bellan A., Bertoglio J., Quillet A., Marchiol C., Wakasugi H., Mishall Z., Fradelizi D. Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation. J Immunol. 1986 Apr 1;136(7):2463–2469. [PubMed] [Google Scholar]
  5. Inamura N., Hashimoto M., Nakahara K., Aoki H., Yamaguchi I., Kohsaka M. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol. 1988 Jan;46(1):82–90. doi: 10.1016/0090-1229(88)90008-6. [DOI] [PubMed] [Google Scholar]
  6. Inamura N., Nakahara K., Kino T., Goto T., Aoki H., Yamaguchi I., Kohsaka M., Ochiai T. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation. 1988 Jan;45(1):206–209. doi: 10.1097/00007890-198801000-00042. [DOI] [PubMed] [Google Scholar]
  7. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987 Sep;40(9):1249–1255. doi: 10.7164/antibiotics.40.1249. [DOI] [PubMed] [Google Scholar]
  8. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987 Sep;40(9):1256–1265. doi: 10.7164/antibiotics.40.1256. [DOI] [PubMed] [Google Scholar]
  9. Manca F., Fenoglio D., Kunkl A., Caltabellotta M., Celada F. Effect of cyclosporine on the antigen-presenting function of human and murine accessory cells. Transplantation. 1988 Aug;46(2 Suppl):40S–43S. doi: 10.1097/00007890-198808001-00008. [DOI] [PubMed] [Google Scholar]
  10. McIntosh L. C., Morrice L. M., Udagawa Y., Thomson A. W. Influence of tumour carriage on the production of lymphokines affecting macrophage behaviour. Immunology. 1986 Mar;57(3):359–365. [PMC free article] [PubMed] [Google Scholar]
  11. Murase N., Todo S., Lee P. H., Lai H. S., Chapman F., Nalesnik M. A., Makowka L., Starzl T. E. Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc. 1987 Oct;19(5 Suppl 6):71–75. [PMC free article] [PubMed] [Google Scholar]
  12. Nalesnik M. A., Todo S., Murase N., Gryzan S., Lee P. H., Makowka L., Starzl T. E. Toxicology of FK-506 in the Lewis rat. Transplant Proc. 1987 Oct;19(5 Suppl 6):89–92. [PMC free article] [PubMed] [Google Scholar]
  13. Ochiai T., Nagata M., Nakajima K., Suzuki T., Sakamoto K., Enomoto K., Gunji Y., Uematsu T., Goto T., Hori S. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation. 1987 Dec;44(6):729–733. doi: 10.1097/00007890-198712000-00001. [DOI] [PubMed] [Google Scholar]
  14. Ochiai T., Nakajima K., Nagata M., Hori S., Asano T., Isono K. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation. 1987 Dec;44(6):734–738. doi: 10.1097/00007890-198712000-00002. [DOI] [PubMed] [Google Scholar]
  15. Palay D. A., Cluff C. W., Wentworth P. A., Ziegler H. K. Cyclosporine inhibits macrophage-mediated antigen presentation. J Immunol. 1986 Jun 15;136(12):4348–4353. [PubMed] [Google Scholar]
  16. Sanghvi A., Warty V., Zeevi A., Diven W., Duquesnoy R., Makowka L., Starzl T. E. FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes. Transplant Proc. 1987 Oct;19(5 Suppl 6):45–49. [PMC free article] [PubMed] [Google Scholar]
  17. Sawada S., Suzuki G., Kawase Y., Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 1987 Sep 15;139(6):1797–1803. [PubMed] [Google Scholar]
  18. Smith K. A., Cantrell D. A. Interleukin 2 regulates its own receptors. Proc Natl Acad Sci U S A. 1985 Feb;82(3):864–868. doi: 10.1073/pnas.82.3.864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Snyder D. S., Wright C. L., Ting C. Inhibition of human monocyte antigen presentation, but not HLA-DR expression, by cyclosporine. Transplantation. 1987 Sep;44(3):407–411. doi: 10.1097/00007890-198709000-00016. [DOI] [PubMed] [Google Scholar]
  20. Stephen M., Woo J., Hasan N. U., Whiting P. H., Thomson A. W. Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. Transplantation. 1989 Jan;47(1):60–65. doi: 10.1097/00007890-198901000-00014. [DOI] [PubMed] [Google Scholar]
  21. Takagishi K., Yamamoto M., Nishimura A., Yamasaki G., Kanazawa N., Hotokebuchi T., Kaibara N. Effects of FK-506 on collagen arthritis in mice. Transplant Proc. 1989 Feb;21(1 Pt 1):1053–1055. [PubMed] [Google Scholar]
  22. Thiru S., Collier D. S., Calne R. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. Transplant Proc. 1987 Oct;19(5 Suppl 6):98–99. [PubMed] [Google Scholar]
  23. Thomson A. W. FK-506--how much potential? Immunol Today. 1989 Jan;10(1):6–9. doi: 10.1016/0167-5699(89)90057-1. [DOI] [PubMed] [Google Scholar]
  24. Todo S., Podesta L., ChapChap P., Kahn D., Pan C. E., Ueda Y., Okuda K., Imventarza O., Casavilla A., Demetris A. J. Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc. 1987 Oct;19(5 Suppl 6):64–67. [PMC free article] [PubMed] [Google Scholar]
  25. Todo S., Ueda Y., Demetris J. A., Imventarza O., Nalesnik M., Venkataramanan R., Makowka L., Starzl T. E. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery. 1988 Aug;104(2):239–249. [PMC free article] [PubMed] [Google Scholar]
  26. Varey A. M., Champion B. R., Cooke A. Cyclosporine affects the function of antigen-presenting cells. Immunology. 1986 Jan;57(1):111–114. [PMC free article] [PubMed] [Google Scholar]
  27. Webster L. M., Thomson A. W. Augmentation of delayed-type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations. Clin Exp Immunol. 1988 Jan;71(1):149–154. [PMC free article] [PubMed] [Google Scholar]
  28. Whisler R. L., Lindsey J. A., Proctor K. V., Newhouse Y. G., Cornwell D. G. The impaired ability of human monocytes to stimulate autologous and allogeneic mixed lymphocyte reactions after exposure to cyclosporine. Associated alterations of HLA-DR expression and physical characteristics of monocytes. Transplantation. 1985 Jul;40(1):57–61. doi: 10.1097/00007890-198507000-00012. [DOI] [PubMed] [Google Scholar]
  29. Woo J., Stephen M., Thomson A. W. Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology. 1988 Sep;65(1):153–155. [PMC free article] [PubMed] [Google Scholar]
  30. Yoshimura N., Matsui S., Hamashima T., Oka T. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation. 1989 Feb;47(2):351–356. doi: 10.1097/00007890-198902000-00034. [DOI] [PubMed] [Google Scholar]
  31. Yoshimura N., Matsui S., Hamashima T., Oka T. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. Transplantation. 1989 Feb;47(2):356–359. doi: 10.1097/00007890-198902000-00035. [DOI] [PubMed] [Google Scholar]
  32. Zeevi A., Duquesnoy R., Eiras G., Rabinowich H., Todo S., Makowka L., Starzl T. E. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc. 1987 Oct;19(5 Suppl 6):40–44. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES